Kseniya Simpson, PhD

Principal

Kseniya is a Principal at Hatteras and focuses on investing in innovative biotech companies. Kseniya currently serves as a board director for Hatteras portfolio companies Trefoil Therapeutics and Ribometrix. She is a board observer for Sensorium Therapeutics, Ten63 Therapeutics, Aer Therapeutics, and Code Bio, and she was previously a board observer for Vigil Neuroscience (acquired by Sanofi).

Prior to Hatteras, Kseniya was with Triangle Insights Group, where she worked as a Strategy Consultant, advising biotech and pharma companies on a wide variety of topics including company and asset diligence, pipeline strategy, clinical development, and commercial preparedness. Kseniya is a scientist by training and has conducted research in the areas of RNA therapeutics, nucleic acid delivery, lipid monolayers, and tissue engineering. She has also worked at Yale Ventures and served as a teaching fellow and lecturer at Yale.

Kseniya earned a Ph.D. in Cellular and Molecular Physiology from Yale University where she worked on siRNA therapeutics under the mentorship of W. Mark Saltzman, Ph.D. and received the Ruth L. Kirschstein National Research Service Award. She holds dual B.S. degrees in Chemistry and Biological Chemistry from the University of Chicago.